To the Editors: Shah et al. ([1][1]) reported on the cardiotoxicity of the histone deacetylase inhibitor Romidepsin (depsipeptide, FK228) administered weekly ×3 q28, in 15 patients with metastatic neuroendocrine tumors. The study was terminated early due to a high number of “serious cardiac
No takes yet. Share an insight, caveat, or question.
Molife et al. (2007) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: